Select Publications
Journal articles
2024, 'More data are needed to confirm the utility of screening for atypical fibroxanthoma and pleomorphic dermal sarcoma recurrence', Journal of the American Academy of Dermatology, 90, pp. e171 - e173, http://dx.doi.org/10.1016/j.jaad.2023.11.064
,2024, 'Alterations to the Hidradenitis Suppurativa Serum Proteome with Spleen Tyrosine Kinase Antagonism: Proteomic Results from a Phase 2 Clinical Trial', Journal of Investigative Dermatology, 144, pp. 786 - 793.e1, http://dx.doi.org/10.1016/j.jid.2023.10.005
,2024, 'Comment on Kridin et al.—Considering both relative and absolute risk differences in infection risk between biologics classes in patients with psoriasis', Journal of the European Academy of Dermatology and Venereology, 38, pp. e351 - e353, http://dx.doi.org/10.1111/jdv.19615
,2024, 'Global consensus process to establish a core dataset for hidradenitis suppurativa registries', British Journal of Dermatology, 190, pp. 510 - 518, http://dx.doi.org/10.1093/bjd/ljad454
,2024, 'The serum proteome of pyoderma gangrenosum is more expansive than that of hidradenitis suppurativa', Journal of the European Academy of Dermatology and Venereology, 38, pp. e348 - e350, http://dx.doi.org/10.1111/jdv.19611
,2024, 'Drug Survival of Biologics in Hidradenitis Suppurativa: A Systematic Review and Meta-Analysis.', J Am Acad Dermatol, http://dx.doi.org/10.1016/j.jaad.2024.03.028
,2024, 'Hidradenitis suppurativa: New insights into disease mechanisms and an evolving treatment landscape', British Journal of Dermatology, 190, pp. 149 - 162, http://dx.doi.org/10.1093/bjd/ljad345
,2024, 'Rapid Attenuation of B-Cell and IFN-γ–Associated Chemokines in Clinical Responders to Jak Inhibition with Upadacitinib in Hidradenitis Suppurativa', Journal of Investigative Dermatology, 144, pp. 416 - 419.e5, http://dx.doi.org/10.1016/j.jid.2023.07.023
,2024, 'Clinical reports: the overarching home for case series and case reports in the BJD', British Journal of Dermatology, 190, pp. 1 - 2, http://dx.doi.org/10.1093/bjd/ljad301
,2024, 'Discrepancies in hidradenitis suppurativa lesion characterization by providers and patients', Journal of the European Academy of Dermatology and Venereology, http://dx.doi.org/10.1111/jdv.19999
,2024, 'Laser capture microdissection provides a novel molecular profile of human primary cutaneous melanoma', Pigment Cell and Melanoma Research, 37, pp. 81 - 89, http://dx.doi.org/10.1111/pcmr.13121
,2024, 'Mast cells are upregulated in hidradenitis suppurativa tissue, associated with epithelialized tunnels and normalized by spleen tyrosine kinase antagonism', Experimental Dermatology, 33, http://dx.doi.org/10.1111/exd.14894
,2024, 'Understanding multi-kinase inhibitor-associated cutaneous ulcers may provide molecular insights into the aetiology of pyoderma gangrenosum: A comment on Jeon et al.', Australasian Journal of Dermatology, http://dx.doi.org/10.1111/ajd.14221
,2023, 'Attenuated PBMC Cytokine Production in Hidradenitis Suppurativa May Be Indicative of Cellular Exhaustion, Providing Novel Biomarkers, and Future Therapeutic Potential', Journal of Investigative Dermatology, 143, pp. 2334 - 2337, http://dx.doi.org/10.1016/j.jid.2023.05.020
,2023, 'Resident cutaneous memory T cells: a clinical review of their role in chronic inflammatory dermatoses and potential as therapeutic targets', British Journal of Dermatology, 189, pp. 656 - 663, http://dx.doi.org/10.1093/bjd/ljad303
,2023, 'Infectious Disease Screening Prior to Systemic Immunomodulatory Therapy in Hidradenitis Suppurativa: Consensus Guidelines from the Asia-Pacific Hidradenitis Suppurativa Foundation.', Dermatology, http://dx.doi.org/10.1159/000534575
,2023, 'Human dermal fibroblast subpopulations and epithelial mesenchymal transition signals in hidradenitis suppurativa tunnels are normalized by spleen tyrosine kinase antagonism in vivo', PLoS ONE, 18, pp. e0282763, http://dx.doi.org/10.1371/journal.pone.0282763
,2023, 'A proof-of-concept open-label clinical trial of spleen tyrosine kinase antagonism using fostamatinib in moderate-to-severe hidradenitis suppurativa', Journal of the American Academy of Dermatology, 89, pp. 694 - 702, http://dx.doi.org/10.1016/j.jaad.2023.05.076
,2023, 'Efficacy of topical diphencyprone for melanoma in-transit metastases: a systematic review and meta-analysis', Melanoma Research, 33, pp. 434 - 436, http://dx.doi.org/10.1097/CMR.0000000000000914
,2023, 'Knowledge, attitudes, and perceptions of hidradenitis suppurativa among young adults in Singapore', JAAD International, 12, pp. 72 - 80, http://dx.doi.org/10.1016/j.jdin.2023.03.010
,2023, 'Obesity and hidradenitis suppurativa: targeting meta-inflammation for therapeutic gain', Clinical and Experimental Dermatology, 48, pp. 984 - 990, http://dx.doi.org/10.1093/ced/llad182
,2023, 'Reply to Tilotta and Bongiorno: Considering the role of resident cutaneous memory T-cell suppression in providing durable atopic dermatitis remission', Journal of the European Academy of Dermatology and Venereology, 37, pp. e1173 - e1174, http://dx.doi.org/10.1111/jdv.19179
,2023, 'The impact of psoriasis biologic therapy on HIV viral load and CD4+ cell counts in HIV-positive individuals: A real-world cohort study', Journal of the European Academy of Dermatology and Venereology, 37, pp. 1659 - 1663, http://dx.doi.org/10.1111/jdv.19020
,2023, 'Treatment of alopecia areata with the janus kinase inhibitor upadacitinib: A retrospective cohort study', Journal of the American Academy of Dermatology, 89, pp. 137 - 138, http://dx.doi.org/10.1016/j.jaad.2022.12.056
,2023, 'Baseline clinical, hormonal and molecular markers associated with clinical response to IL-23 antagonism in hidradenitis suppurativa: A prospective cohort study', Experimental Dermatology, 32, pp. 869 - 877, http://dx.doi.org/10.1111/exd.14789
,2023, 'Maintenance of response to dupilumab in prurigo nodularis: A retrospective cohort study', JAAD International, 11, pp. 143 - 144, http://dx.doi.org/10.1016/j.jdin.2023.02.006
,2023, 'Academic dermatology in Australia and New Zealand between 2017 and 2022: A cross-sectional bibliometric analysis', Australasian Journal of Dermatology, 64, pp. 213 - 220, http://dx.doi.org/10.1111/ajd.14025
,2023, 'In search of therapeutic biomarkers to interleukin-23 antagonism in hidradenitis suppurativa', British Journal of Dermatology, 188, pp. 588 - 589, http://dx.doi.org/10.1093/bjd/ljad027
,2023, 'Angiotensin-converting enzyme 2 expression is elevated in tissue of hidradenitis suppurativa and pyoderma gangrenousm and demonstrates a different pattern of expression to psoriasis vulgaris', Journal of the European Academy of Dermatology and Venereology, 37, pp. e372 - e374, http://dx.doi.org/10.1111/jdv.18543
,2023, 'Monkeypox: Cutaneous clues to clinical diagnosis', Journal of the American Academy of Dermatology, 88, pp. 698 - 700, http://dx.doi.org/10.1016/j.jaad.2022.08.048
,2023, 'Strongyloides screening prior to dupilumab therapy in atopic dermatitis: a retrospective cohort study evaluating screening utility', British Journal of Dermatology, 188, pp. 294 - 295, http://dx.doi.org/10.1093/bjd/ljac060
,2023, 'Dupilumab-associated head and neck dermatitis resolves temporarily with itraconazole therapy and rapidly with transition to upadacitinib, with Malassezia-specific immunoglobulin E levels mirroring clinical response', Journal of the American Academy of Dermatology, 88, pp. 255 - 257, http://dx.doi.org/10.1016/j.jaad.2022.05.021
,2023, '1323 Human dermal fibroblasts and mast cell populations are altered in hidradenitis suppurativa, with epithelial-mesenchymal-transition signals ameliorated by spleen tyrosine kinase antagonism.', Journal of Investigative Dermatology, 143, pp. S227 - S227, http://dx.doi.org/10.1016/j.jid.2023.03.1339
,2023, 'LB1700 SYK antagonism in hidradenitis suppurativa demonstrates clinical efficacy with grearter response in B-cell predominant disease: Results of a open-label, proof-of-concept phase 2 clinical trial', Journal of Investigative Dermatology, 143, pp. B15 - B15, http://dx.doi.org/10.1016/j.jid.2023.06.074
,2022, 'Adalimumab therapy is associated with increased faecal short chain fatty acids in hidradenitis suppurativa', Experimental Dermatology, 31, pp. 1872 - 1880, http://dx.doi.org/10.1111/exd.14665
,2022, 'Real-world safety and clinical response of Janus kinase inhibitor upadacitinib in the treatment of hidradenitis suppurativa: A retrospective cohort study', Journal of the American Academy of Dermatology, 87, pp. 1440 - 1442, http://dx.doi.org/10.1016/j.jaad.2022.07.047
,2022, 'Metabolic syndrome and hidradenitis suppurativa: epidemiological, molecular, and therapeutic aspects', International Journal of Dermatology, 61, pp. 1175 - 1186, http://dx.doi.org/10.1111/ijd.15910
,2022, 'The road to biologics in patients with hidradenitis suppurativa: a nationwide drug utilization study*', British Journal of Dermatology, 187, pp. 523 - 530, http://dx.doi.org/10.1111/bjd.21673
,2022, 'Can we increase the drug survival time of biologic therapies in hidradenitis suppurativa?', Clinical and Experimental Dermatology, 47, pp. 1585 - 1586, http://dx.doi.org/10.1111/ced.15232
,2022, 'Interleukin-17RA blockade by brodalumab decreases inflammatory pathways in hidradenitis suppurativa skin and serum', British Journal of Dermatology, 187, pp. 223 - 233, http://dx.doi.org/10.1111/bjd.21060
,2022, 'Amplicon sequencing demonstrates comparable follicular mycobiomes in patients with hidradenitis suppurativa compared with healthy controls', Journal of the European Academy of Dermatology and Venereology, 36, pp. e580 - e583, http://dx.doi.org/10.1111/jdv.18075
,2022, 'Guidance on COVID-19 Vaccination in Hidradenitis Suppurativa Patients: A Modified Delphi Consensus of Experts', Skin Appendage Disorders, 8, pp. 287 - 290, http://dx.doi.org/10.1159/000521268
,2022, 'A case series of early biologic therapy in guttate psoriasis: Targeting resident memory T cell activity as a potential novel therapeutic modality', JAAD Case Reports, 24, pp. 82 - 87, http://dx.doi.org/10.1016/j.jdcr.2022.04.019
,2022, 'Dupilumab-associated head and neck dermatitis is associated with elevated pretreatment serum Malassezia-specific IgE: a multicentre, prospective cohort study', British Journal of Dermatology, 186, pp. 1050 - 1052, http://dx.doi.org/10.1111/bjd.21019
,2022, 'Extramammary Paget's disease Harbinger of internal malignancy', Australian Journal of General Practice, 51, pp. 351 - 352, http://dx.doi.org/10.31128/AJGP-05-21-5981
,2022, 'Large-scale serum analysis identifies unique systemic biomarkers in psoriasis and hidradenitis suppurativa*', British Journal of Dermatology, 186, pp. 684 - 693, http://dx.doi.org/10.1111/bjd.20642
,2022, 'Pyoderma gangrenosum: A systematic review of the molecular characteristics of disease', Experimental Dermatology, 31, pp. 498 - 515, http://dx.doi.org/10.1111/exd.14534
,2022, 'Autoantibody-Mediated Macrophage Responses Provide the Missing Link between Innate and Adaptive Immune Dysfunction in Hidradenitis Suppurativa', Journal of Investigative Dermatology, 142, pp. 747 - 749, http://dx.doi.org/10.1016/j.jid.2021.08.400
,2022, 'Dermatology and wound research: Targeting inflammation through cooperation and collaboration', Wound Practice and Research, 30, pp. 5, http://dx.doi.org/10.33235/wpr.30.1.5
,2022, 'Identification of Biomarkers and Critical Evaluation of Biomarker Validation in Hidradenitis Suppurativa: A Systematic Review', JAMA Dermatology, 158, pp. 300 - 313, http://dx.doi.org/10.1001/jamadermatol.2021.4926
,